Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET
Company Participants
Jaclyn Jaffe – Senior Director, Corporate Operations
Claude Maraoui – Co-Founder, President and CEO
Joseph Benesch – CFO
Srinivas Sidgiddi – VP, R&D
Louis Donati – Director, Market Access
Conference Call Participants
Thomas Flaten – Lake Street Capital Markets
Scott Henry – AGP
Brandon Folkes – Rodman & Renshaw
Jason Wittes – ROTH Capital
Kalpit Patel – B. Riley Securities
Operator
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical’s 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of this call will be available approximately one hour after the end of the call for approximately 30 days.
I would now like to turn the call over to Jaclyn Jaffe, the company’s Senior Director of Corporate Operations. Please go ahead.
Jaclyn Jaffe
Good afternoon, and thank you for participating in today’s conference call. Joining me from Journey Medical’s leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; and Joseph Benesch; Chief Financial Officer. Joining for the Q&A portion of the call will be Ramsey Alloush, General Counsel and Corporate Secretary; Dr. Srinivas Sidgiddi, Vice President of Research and Development, and Louis Donati, Director of Market Access.
During this call management will be making forward-looking statements including statements that address, among other things, Journey Medical’s expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more
